Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Sales (2016 - 2025)

Historic Return on Sales for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to 1.23%.

  • Enanta Pharmaceuticals' Return on Sales rose 7300.0% to 1.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.25%, marking a year-over-year increase of 4600.0%. This contributed to the annual value of 1.25% for FY2025, which is 4600.0% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Return on Sales is 1.23%, which was up 7300.0% from 1.0% recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Return on Sales high stood at 1.0% for Q2 2025, and its period low was 2.12% during Q1 2023.
  • For the 5-year period, Enanta Pharmaceuticals' Return on Sales averaged around 1.51%, with its median value being 1.48% (2023).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Return on Sales tumbled by -15800bps in 2021 and then skyrocketed by 8100bps in 2024.
  • Enanta Pharmaceuticals' Return on Sales (Quarter) stood at 1.09% in 2021, then decreased by -13bps to 1.23% in 2022, then crashed by -51bps to 1.86% in 2023, then grew by 29bps to 1.31% in 2024, then rose by 6bps to 1.23% in 2025.
  • Its last three reported values are 1.23% in Q3 2025, 1.0% for Q2 2025, and 1.52% during Q1 2025.